Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Inclusion Criteria: 1. Body mass index (BMI) ≥20 to ≤35 kg/m2 and total body weight \>50 kg(male) or \>45kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared); 2. Ability to understand and willingness to sign a written informed consent form; 3. Normal physical examination, vital signs, 12-lead ECG, and clinical laboratory values, or any abnormality that is non-clinically significant. Exclusion Criteria: 1. Participants with a history of hypersensitivity to study drug or any component of study medication; 2. Participants had taken prescription, over-the-counter, herbal, or vitamin products within 4 weeks prior to screening； 3. Smoking more than 5 cigarettes per day within 12 weeks prior to screening，or who cannot stop using any tobacco products during the study period; 4. Participants who donated blood/bleeding profusely (\> 400 mL) 12 weeks prior to randomization; 5. Those with clinically significant Electrocardiogram(ECG) abnormalities, or QTcF \> 450ms; 6. Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse. 7. Females who are pregnant, lactating, or likely to become pregnant during the study. 8. History of dysphagia or any gastrointestinal disorder that affect absorption